Global Vaccine Market

Vaccine Market Insights

Vaccination has played the most crucial role to maintain the sustainability of the global population. Vaccines are used in various strategies related to disease prevention and have the potential to completely transform health by eliminating the threat from deadly infectious disease. In comparison to the pharmaceutical sector, vaccine sectors hold a relatively small and concrete percentage population both from the demand and supply parameter. The vaccine market is highly regulated and largely dependent on public purchase and donor policies. The various case studies show that the vaccine market is expected to grow at a higher CGAR percentage of 8.5 between 2020-2026 duration. The maximum global vaccine comes from the merger and partnership of multiple companies which is boosting the production rate and sales of the product on a global scale. The high prevalence of infectious disease and the growing focus on immunization is creating the demand for the product. Government investment to bring immunization to every stratum of society is building opportunities for the growth of the product. A global pandemic has affected more than 200 million of the global population. This created pressure on the manufacturing companies led to an increased production rate and escalate the supply chain of the product. The expansion of manufacturing commodities facilitates catering to the demand will further strengthen the core potential of many industries. However, the pandemic has brought a halt to the ongoing immunization programs organized by many national and international organizations. Thus this program suspension and decrease in vaccination rate have built up huge pressure on the entire healthcare system thus making the population more susceptible to catch deadly antigens and leading to vaccine production to rise 

Vaccine Market: By Technology

Based on the technology the vaccine market can be studied as live attenuated vaccines, toxoid vaccines, recombinant vaccines, inactivated vaccines, and other vaccines. Out of the mentioned list, the inactivated vaccines have shown the highest market since past recent times. The associated benefits of having extreme stability along with pro-longed shelf life are triggering the inactivated vaccine market to grow. Inactivated vaccines are in high demand for influenza and hepatitis A & B vaccines in economically emerging countries which contributes to the major chunk of revenue as compared to other segments.

Vaccine Market: By Disease

Vaccines cover a wide range of diseases that can be bifurcated into pneumococcal, influenza, DTP, rotavirus, TT, polio, MMR, varicella, dengue, and TB among others. Diseases such as pneumococcal, DTP, and others come under bacterial diseases which holds the largest market share of the vaccines. The high sale of bacterial diseases across the globe is building the demand for the product. Also, these are the first line immunization for the newborns therefore uplifting the market in the pediatrics population.

However viral diseases such as influenza, HIV, and others are expected to be the future market builders of the vaccines owing increasing percentage of viral diseases in regions such as East Africa, North America.  

Vaccine Market: By Route

IM, SC, ID, and oral are the routes of vaccination. The intramuscular and intra-cutaneous administration accounts for the largest vaccine market share of 2019 and is estimated to witness the same growth in the aforementioned timeline owing to the increased prevalence of bacterial and viral diseases. This route provides a better immune response with a lower rate of reaction at the injection site. However, in comparison, oral vaccination showed a slower growth due to associated challenges faced in many developing regions.   

Vaccine Market: By Patient

Pediatric and adult are the two patient classifications of the vaccine market. Pediatric holds the largest market of the vaccine in terms of value. The two prime reasons behind the significant growth are increasing pediatric vaccination dosage and increasing statistics of birth. Growing initiatives taken by the government for immunization and the rising prevalence of diseases in this segment is adding values to the vaccine market. The adult segment is growing owing to demand in the R & D sector and a strong base with upcoming collaborations and product launch which is likely to trigger the vaccine demand.

Vaccine Market: By Region

North America showed the highest market share of vaccines in the year 2019 and is expected to maintain dominance in the coming years also. The presence of strong manufacturers, awareness about the product, and secure government policies for the welfare of their population's health are the reasons behind the vaccine market in the region. the increasing prevalence of diseases due to changing environmental conditions making it more favorable for the growth of the micro-organisms is adding numbers to the demand for the product.

Countries of the Asia-Pacific region such as India and China are having a large percentage population that triggers the demand for vaccines and economic development further pushes the revenue of the vaccine market in the region and hence will grow the fastest from 2020 to 2026.

Vaccine Market Share and Competitor Analysis

Pfizer, Inc., Sanofi Pasteur SA, Merck & Co., Inc., Emergent BioSolutions, Inc., CSL Limited,  GlaxoSmithKline plc., Johnson & Johnson, Serum Institute of India, Bavarian Nordic, AstraZeneca, Daiichi Sankyo Company, Limited, and Mitsubishi Tanabe Pharma Corporation among others are top companies in the vaccine market.

Please note: This is not an exhaustive list of companies profiled in the report.

In October 2020, GlaxoSmithKline plc and Sanofi have come together to sign a statement of intent with Garvi, which is the legal administrator of COVAX facilities. Both the firms are come together to fight against coronavirus by building production units for 200 million doses. The doses are specially designed adjuvant recombinant COVID-19 vaccine based on protein. 

In September 2020, Serum Institute of India collaborated with Gavi, to produce around 100 million COVID-19 vaccines for India by 2021.

Check the Press Release on Global Vaccine Market Report